
    
      Study A8121018 was prematurely discontinued due to FDA instructions stating that Study
      A8121018 could not be performed under US IND 78,910, which was provided by the meeting on
      August 13, 2009. And then the termination was decided by Pfizer on September 8, 2009 prior to
      subject dosing with PF-00868554. There were no safety concerns regarding the study in the
      decision to terminate the trial.
    
  